NCT04090658 - A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2019

Primary Completion Date

January 10, 2020

Study Completion Date

December 11, 2020

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B

Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV\_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.

DRUG

Placebo

Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.

Trial Locations (1)

812-0025

GSK Investigational Site, Fukuoka